WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE [Canadian Business Journal (Canada)]
CNS Pharmaceuticals, Inc. (CNSP)
Company Research
Source: Canadian Business Journal
VANCOUVER, British Columbia, March 13, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. Company GBM In the Phase 1 trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response, which is defined by the National Cancer Institute as the disappearance of all signs of cancer in response to treatment. This initial trial was conducted in 2006 and as of 20, the patient has remained cancer free for over 13 years. “ We are delighted to provide this update on Berubicin’s potential capabilities as we continue to develop the drug We are very encouraged by these results and remain hopeful in our efforts to treat GBM, Mariusz Olejniczak, CEO of WPD We are looking forward to initiating the Phase 2 clinical trial in the second half of this year with our partner, CNS Pharmaceuticals Inc
Show less
Read more
Impact Snapshot
Event Time:
CNSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNSP alerts
High impacting CNS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CNSP
News
- CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)Accesswire
- CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- CNS Pharmaceuticals Reports Third Quarter 2024 Financial ResultsAccesswire
- CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment [Yahoo! Finance]Yahoo! Finance
- CNS Pharmaceuticals Announces Virtual Investor KOL Connect SegmentAccesswire
CNSP
Sec Filings
- 11/15/24 - Form DEFR14A
- 11/14/24 - Form 10-Q
- 11/14/24 - Form SC
- CNSP's page on the SEC website